Study details
Enrolling now
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Brigham and Women's Hospital
NCT IDNCT06489548ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
16
Study length
about 1.7 years
Ages
60–85
Locations
1 site in MA
About this study
This trial is testing the safety and tolerability of Foralumab, a medication that targets immune cells in the brain. The goal is to see if this treatment can improve cognition in people with mild cognitive impairment due to early Alzheimer's or dementia by modulating microglial activation.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Foralumab TZLS-401 100 µg
- 2.Take Foralumab TZLS-401 50 µg
PhasePhase 2
Primary goalAssessment of microglial function via PET scan using the ligand [18F]PBR06
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Assessment of microglial function via PET scan using the ligand [18F]PBR06, The number of adverse events in drug versus placebo groups.
Body systems
Neurology